Terrie Curran insider trades: Arcutis Biotherapeutics (ARQT) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Terrie reports to the SEC
Open-market buys and sales
16 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 27, 2026 | ARQT | ↓ Sell | 38,200 | $25.03 | $956K | Direct | Aug 28, 2026 (1d) |
| Aug 20, 2026 | ARQT | ↓ Sell | 1,072 | $26.04 | $28K | Direct | Aug 24, 2026 (4d) |
| Jan 21, 2025 | PHAT | ↓ Sell | 19,109 | $6.59 | $126K | Direct | Jan 23, 2025 (2d) |
| Nov 11, 2024 | ARQT | ↓ Sell | 8,687 | $10.85 | $94K | Direct | Nov 13, 2024 (2d) |
| Jul 15, 2024 | PHAT | ↓ Sell | 33,848 | $11.72 | $397K | Direct | Jul 17, 2024 (2d) |
| Mar 22, 2024 | PHAT | ↓ Sell | 16,851 | $9.11 | $154K | Direct | Mar 26, 2024 (4d) |
| Apr 6, 2023 | PHAT | ↑ Buy | 12,919 | $7.82 | $101K | Direct | Apr 7, 2023 (1d) |
| Mar 1, 2023 | PHAT | ↓ Sell | 1,436 | $8.54 | $12K | Direct | Mar 3, 2023 (2d) |
| Jan 20, 2023 | PHAT | ↓ Sell | 5,821 | $8.20 | $48K | Direct | Jan 20, 2023 (0d) |
| Nov 21, 2022 | PHAT | ↓ Sell | 1,526 | $9.60 | $15K | Direct | Nov 23, 2022 (2d) |
| May 13, 2022 | PHAT | ↑ Buy | 20,500 | $7.41 | $152K | Direct | May 16, 2022 (3d) |
| Sep 9, 2021 | MYOV | ↓ Sell10b5-1 | 4,850 | $25.58 | $124K | Direct | Sep 13, 2021 (4d) |
| Sep 2, 2021 | MYOV | ↓ Sell10b5-1 | 48,508 | $25.02 | $1.2M | Direct | Sep 3, 2021 (1d) |
| Mar 22, 2021 | PHAT | ↓ Sell | 11,513 | $43.32 | $499K | Direct | Mar 23, 2021 (1d) |
| Sep 18, 2019 | CELG | ↓ Sell | 11,338 | $98.27 | $1.1M | Direct | Sep 19, 2019 (1d) |
| Sep 25, 2017 | CELG | ↓ Sell10b5-1 | 1,727 | $143.89 | $248K | Direct | Sep 26, 2017 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ARQT insiders
Open-market trades in the last 12 months
About Terrie Curran's insider trades
Terrie Curran is a director at Arcutis Biotherapeutics (ARQT). Since Sep 25, 2017, Terrie has reported 2 open-market purchases worth $253K and 14 sales worth $5.0M on SEC Form 4. In the last 12 months: 2 sales ($984K).
3 sales (32% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (34 filings), option exercises (12 filings), shares withheld for taxes (6 filings), shares returned to the company (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ARQT insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.